Drug updated on 4/10/2024
| Dosage Form | Injection (intravenous; 50 mg) |
| Drug Class | CD30-directed anitbody-drug conjugates |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine in adult patients.
- For the treatment of classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as postautologous hematopoietic stem cell transplantation (auto-HSCT) consolidation in adult patients.
- For the treatment of classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates in adult patients.
- For the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone in adult patients.
- For the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen in adult patients.
- For the treatment of primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy in adult patients.
Summary
- Brentuximab vedotin (Adcetris) is indicated for the treatment of various types of lymphoma, including previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), cHL at high risk of relapse or progression post-autologous hematopoietic stem cell transplantation, and systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
- The information was derived from 10 systematic reviews/meta-analyses. These studies provided a comparison between brentuximab vedotin and other drugs based on safety and effectiveness in treating different subtypes of lymphomas.
- In terms of effectiveness in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL), brentuximab vedotin has shown superior efficacy as a salvage treatment compared to salvage chemotherapy post-autologous stem cell transplantation. It achieved an overall response rate (ORR) of 62.6% and a complete response rate (CR) of 32.9% after four treatment cycles with meaningful outcomes for progression-free survival rates.
- Regarding its safety profile, common adverse events associated with brentuximab vedotin were hematological toxicities such as neutropenia, anemia, thrombocytopenia, grade ≥3 peripheral neuropathy, which aligns with the known side-effect profile; it also significantly increased the risk of all-grade peripheral sensory neuropathy, pyrexia, nausea, vomiting, diarrhea, and alopecia when compared to non-brentuximab therapies.
- For advanced-stage Hodgkin Lymphoma patients, the combination therapy involving brentuximab vedotin showed improved efficacy over the ABVD regimen while maintaining tolerability; however, no direct comparison data was available against the BEACOPP regimen, but A+AVD appeared to be a more tolerable option.
- Brentuximab vedotin-containing regimens demonstrated high response rates with manageable toxicity profiles in older adults, although attention to specific toxicities such as peripheral neuropathy is crucial.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Adcetris (brentuximab vedotin) Prescribing Information. | 2023 | Seattle Genetics Inc., Bothell, WA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| EORTC consensus recommendations for the treatment of mycosis fungoides/S´ezary syndrome – Update 2023. | 2023 | European Journal of Cancer |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma | 2020 | Journal of Immunotherapy of Cancer |
| Hodgkin lymphoma, version 2.2020 | 2020 | Journal of the National Comprehensive Cancer Network |